错配修复缺陷作为子宫内膜癌辅助放疗反应的预测标志物
本研究为回顾性多中心队列研究,纳入128例经组织病理学确诊的IB/II期、3级子宫内膜样子宫内膜癌患者,其中57例(43.0%)为错配修复缺陷型。多变量分析显示,辅助放疗与错配修复缺陷患者疾病特异性生存改善相关(HR 0.19,95%CI 0.05-0.77),而在错配修复完整患者中无显著关联(HR 0.92,95%CI 0.37-2.31)。结论认为错配修复状态可作为预测生物标志物,用于筛选最受益于辅助放疗的患者。
要点
- 128例IB/II期3级子宫内膜样子宫内膜癌中,57例(43.0%)为错配修复缺陷型。
- 错配修复缺陷患者接受辅助放疗后疾病特异性生存改善(HR 0.19,95%CI 0.05-0.77)。
- 错配修复完整患者辅助放疗与疾病特异性生存无显著关联(HR 0.92,95%CI 0.37-2.31)。
核心结论
- 辅助放疗改善了错配修复缺陷型子宫内膜样子宫内膜癌患者的生存。
- 错配修复状态可作为预测生物标志物,用于筛选最受益于辅助放疗的患者。
研究设计与样本
- 回顾性多中心队列研究,比较经组织病理学确诊的IB/II期、3级子宫内膜样子宫内膜癌患者接受与未接受辅助放疗的情况。
- 共分析128例患者,其中57例(43.0%)为错配修复缺陷型;采用ProMisE分类将肿瘤分为错配修复缺陷、POLE、p53abn或p53wt。
- 使用多变量Cox回归分析探讨辅助治疗与结局之间的关联。
主要发现
- 错配修复缺陷型患者中II期比例高于错配修复完整型(36.8% vs. 15.5%,p=0.006),其余基线特征可比。
- 82例(64.1%)接受辅助放疗,其中外照射55例、阴道近距离放疗27例。
- 多变量分析中,辅助放疗与错配修复缺陷患者疾病特异性生存改善相关(HR 0.19,95%CI 0.05-0.77)。
- 多变量分析中,辅助放疗与错配修复完整患者疾病特异性生存无显著关联(HR 0.92,95%CI 0.37-2.31)。
临床怎么用
- 作者认为错配修复状态可作为预测生物标志物,用于筛选最受益于辅助放疗的子宫内膜样子宫内膜癌患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mismatch repair (MMR) deficiency is found in 20 to 40% of endometrial cancers (ECs) and was recently identified as a discerning feature of one of the four prognostic subgroups identified by The Cancer Genome Atlas. There is accumulating evidence that MMR proteins are involved in the DNA repair processes following radiotherapy. We investigated the predictive value of MMR status for response to adjuvant radiotherapy in patients with stage IB/II, grade 3 endometrioid endometrial cancer (EEC). METHODS: A retrospective multicenter cohort study was performed to compare patients with histopathologically confirmed stage IB/II grade 3 EEC with and without adjuvant radiotherapy. Patients were classified according to the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) identifying ECs as either MMR-deficient, POLE, p53abn or p53wt. Multivariable Cox regression analysis explored associations between adjuvant treatment and outcome. RESULTS: A total of 128 patients were analyzed, including 57 patients (43.0%) with MMR-deficient EECs. Baseline characteristics were comparable, except a higher proportion of MMR-deficient EECs were stage II (36.8% vs. 15.5%, p = 0.006). Eighty-two patients (64.1%) received adjuvant radiotherapy (external beam [n = 55], vaginal brachytherapy [n = 27]). In multivariable analysis, adjuvant radiotherapy was associated with improved disease-specific survival in patients with MMR-deficient EECs (hazard ratio 0.19, 95%-CI 0.05-0.77), but not in patients with MMR-proficient EECs (hazard ratio 0.92, 95%-CI 0.37-2.31). CONCLUSION: Adjuvant radiotherapy improved survival in patients with MMR-deficient EECs. MMR status could be used as a predictive biomarker to select patients that benefit most from adjuvant radiotherapy.
引用
- Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019. PMID: 31103324. doi:10.1016/j.ygyno.2019.03.097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。